ArticleEvidence-based dentistry2026
Chemically modified curcumin in periodontal therapy: a scoping review.
Article in Evidence-based dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LPS-Induced TNF-α and IL-1 Signaling in Periodontitis: Molecular Mechanisms and Therapeutic Opportunities.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
objectivesPeriodontitis, a multifactorial chronic inflammatory disease that destroys the supporting structures of the teeth, is conventionally managed with treatments focusing on biofilm removal; however, these therapies do not fully address the dysregulated host response central to disease progression. To address this, chemically modified curcumin (CMC) analogues have been developed by modifying curcumin, a derivative of Curcuma longa, a host-modulating agent with potent anti-inflammatory and antioxidant properties. Recently, CMCs have been used to manage periodontitis. This scoping review systematically maps the available evidence on the therapeutic potential of CMCs and their analogues in managing periodontal disease.
methodsA comprehensive literature search in online databases (PubMed, EMBASE, Scopus and Web of Science) using the keywords "chemically modified curcumin" AND "periodontitis" yielded 76 results. Among them, 15 original research studies that evaluated the effects of CMC analogues on periodontitis were reviewed according to the PRISMA-ScR guidelines.
resultsCMC2.24 was the most common analogue studied, followed by CMC 2.5, the mono-carbonyl analogue of curcumin (e.g., 1A) and iron-curcumin nanoparticles. They produced consistent anti-inflammatory and bone-protective effects across multiple in vitro, ex vivo and animal models. They suppressed the pathologically elevated MMP-9 and pro-inflammatory cytokines, including IL-1β, TNF-α and IL-6. Furthermore, they enhanced pro-resolving mediators, such as Resolvin D1. CMCs were superior to traditional curcumin, owing to their improved stability and bioavailability. DISCUSSION: Analysis of the extracted data from the included studies revealed that the CMC analogues effectively reduced excessive inflammation, tissue degradation and dysregulated immune response in periodontitis.
conclusionCMC2.24 was a promising host-modulating agent in periodontal therapy. However, the results are mainly derived from preclinical studies and further human clinical trials are required to apply CMCs into everyday practice.
Identifiers
42595837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.